Ocular Hypertension - Pipeline Insight, 2025

DelveInsight’s, “Ocular Hypertension - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ocular Hypertension: Understanding

Ocular Hypertension: Overview

Ocular hypertension is a condition characterized by elevated pressure inside the eye, which occurs when the aqueous humor, a fluid responsible for nourishing the eye and maintaining its shape, doesn't drain properly. Although individuals with ocular hypertension often experience no noticeable symptoms or changes to their vision, the condition can increase the risk of developing glaucoma, a more serious eye disorder that causes structural damage and potential vision loss. While ocular hypertension does not always progress to glaucoma, regular monitoring by an eye care professional is essential to detect any early signs of damage and manage the condition effectively. Lifestyle factors, such as diet and stress levels, may also play a role in managing eye pressure, though medication or other treatments may be necessary for some individuals. Early intervention can help prevent long-term damage and preserve vision.

Increased intraocular pressure can result from either an excess of fluid entering the eye or a reduced ability of the eye to drain fluid properly. Several conditions can interfere with the normal drainage of aqueous humor, leading to elevated pressure. One such cause is uveitis, an inflammation of the middle portion of the eye, which can affect fluid drainage. Pigment dispersion syndrome occurs when tiny pigment particles from the iris float around inside the eye, potentially blocking the trabecular meshwork, the primary drainage system for the aqueous humor. Pseudoexfoliation syndrome, characterized by the buildup of microscopic protein fibers within the eye, can also obstruct fluid flow. Other causes include the presence of tumors or large cataracts that block drainage pathways, damage caused by eye injury or surgery, and certain medications, particularly corticosteroids. Additionally, chronic angle-closure, in which the iris blocks the trabecular meshwork, can hinder the outflow of aqueous humor, increasing intraocular pressure.

Several factors can increase the risk of developing ocular hypertension. Individuals aged 40 or older are at greater risk, as are those with a family history of ocular hypertension or glaucoma. People with severe nearsightedness (myopia) or farsightedness (hyperopia) are also more prone to elevated eye pressure. Additionally, conditions like diabetes and high blood pressure can contribute to higher risk. Eye injuries, previous eye surgeries, or eye injections may also increase susceptibility. Long-term use of steroid medications is a known risk factor, as are specific eye conditions such as pigment dispersion syndrome and pseudoexfoliation syndrome. Certain medications, like topiramate, may also raise the likelihood of developing ocular hypertension.

Ocular hypertension doesn't always require treatment, but doctors assess the patient's risk of developing glaucoma over the next five to ten years to determine the best approach. If the risk is moderate to high, treatment is usually recommended to prevent damage to the optic nerve. If the risk is low, doctors typically prefer to monitor the condition instead. When treatment is necessary, the most common approach is prescribing eye drops to lower intraocular pressure by 20% to 25%. These drops can include prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, and netarsudil (a rho-kinase inhibitor). In some cases, laser surgery may be considered to help reduce intraocular pressure, although most patients won't require this intervention.

""Ocular Hypertension- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Hypertension pipeline landscape is provided which includes the disease overview and Ocular Hypertension treatment guidelines. The assessment part of the report embraces, in depth Ocular Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Hypertension.

Ocular Hypertension Emerging Drugs Chapters

This segment of the Ocular Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ocular Hypertension Emerging Drugs

• Sepetaprost: Santen Pharmaceutical

Sepetaprost (STN1012600) is a dual agonist of the FP and EP3 receptors, using as its active ingredient sepetaprost, a compound originally developed and manufactured by Ono Pharmaceutical Co., Ltd. STN1012600 is a prostaglandin derivative for the treatment of glaucoma and ocular hypertension that contains 0.002% sepetaprost and has a novel mechanism of action for lowering intraocular pressure. It works by selectively binding to both the FP and EP3 receptors in the eye, promoting increased aqueous humor outflow through both the uveoscleral and trabecular pathways. This dual action helps to lower intraocular pressure more effectively. By targeting these specific receptors, STN1012600 may offer improved efficacy with fewer side effects compared to traditional treatments. Currently, the drug is in Preregistration stage of its development for the treatment of Ocular Hypertension.

• NCX 470: Nicox Ophthalmics, Inc.

NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signaling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs. Currently, the drug is in Phase III stage of its development for the treatment of Ocular Hypertension.

• QLS-111: Qlaris Bio, Inc.

QLS-111 is a novel formulation developed by Qlaris Bio that utilizes an ATP-sensitive potassium (KATP) channel modulator platform to effectively lower intraocular pressure (IOP). Its mechanism of action involves relaxing the vascular and vascular-like tissues located distal to the trabecular meshwork, which leads to a reduction in distal outflow resistance. By enhancing the outflow of aqueous humor, QLS-111 simultaneously lowers episcleral venous pressure (EVP), a critical factor that contributes significantly to IOP. This dual action not only helps to alleviate the pressure within the eye but also addresses an often-overlooked component of IOP regulation, potentially offering a more comprehensive approach to managing conditions such as glaucoma and ocular hypertension. Currently, the drug is in Phase II stage of its development for the treatment of Ocular Hypertension.

• H-1337: Allysta Pharmaceuticals

H-1337 is an advanced multi-kinase inhibitor under development for the treatment of glaucoma and ocular hypertension, designed to lower intraocular pressure (IOP) through a novel mechanism of action. This compound primarily inhibits leucine-rich repeat kinase 2 (LRRK2), a serine/threonine kinase that plays a vital role in regulating the cytoskeletal dynamics of trabecular meshwork cells. By inhibiting LRRK2, H-1337 promotes the depolymerization of microtubules within these cells, leading to structural changes that enhance aqueous humor drainage through the trabecular meshwork and Schlemm's canal. Additionally, H-1337 also exhibits secondary activity as a Rho-associated protein kinase (ROCK) inhibitor, further contributing to its efficacy in reducing IOP. This dual-action approach not only addresses the primary challenge of elevated IOP in glaucoma patients but also positions H-1337 as a promising candidate for improving overall ocular health. Currently, the drug is in Phase II stage of its development for the treatment of Ocular Hypertension.

• RTC-1119: Ripple Therapeutics

RTC-1119 is an innovative intracameral implant developed by Ripple Therapeutics for the treatment of primary open-angle glaucoma. This formulation utilizes a unique prodrug of latanoprost acid, designed to provide sustained release of the active drug through a surface erosion mechanism. The implant is engineered to dissolve gradually, allowing for controlled and predictable drug delivery over an extended period, typically exceeding six months. By enhancing the outflow of aqueous humor and reducing intraocular pressure (IOP), RTC-1119 aims to improve patient compliance and therapeutic outcomes in managing glaucoma. The absence of polymers in its composition further minimizes potential inflammatory responses, making RTC-1119 a promising candidate in the evolving landscape of glaucoma therapies. Currently, the drug is in Preclinical stage of its development for the treatment of Ocular Hypertension.

Further product details are provided in the report……..

Ocular Hypertension: Therapeutic Assessment

This segment of the report provides insights about the different Ocular Hypertension drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Ocular Hypertension
• There are approx. 50+ key companies which are developing the therapies for Ocular Hypertension. The companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. Preregistration include, Santen Pharmaceutical.
• Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ocular Hypertension: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Ocular Hypertension therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Hypertension drugs.

Ocular Hypertension Report Insights

• Ocular Hypertension Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ocular Hypertension Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ocular Hypertension drugs?
• How many Ocular Hypertension drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Hypertension?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ocular Hypertension therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ocular Hypertension and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Santen Pharmaceutical
• Nicox Ophthalmics, Inc.
• Allysta Pharmaceuticals
• Qlaris Bio, Inc
• Ripple Therapeutics
• Laboratoires Thea
• Ocular Therapeutix, Inc.
• Otsuka Beijing Research Institute
• Alcon Research
• AbbVie
• Glaukos Corporation
• MediPrint Ophthalmics
• Ocuphire Pharma

Key Products

• Sepetaprost
• NCX 470
• QLS-111
• H-1337
• RTC-1119
• T4090
• OTX-TIC
• OPC-1085EL
• AR-17043
• AGN-193408 SR
• iDose TREX
• LL-BMT1
• Nyxol

Please Note: It will take 3-4 business days to complete the report upon order confirmation.